Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-Ku, Nagoya-Shi, Aichi-Ken, 464-8681, Japan.
Department of Breast and Endocrine Surgery, Toranomon Hospital, Minato, Tokyo, Japan.
Breast Cancer. 2024 Nov;31(6):1130-1136. doi: 10.1007/s12282-024-01630-1. Epub 2024 Sep 23.
Tailored axillary surgery (TAS) is a new approach for selective removal of metastatic lymph nodes. This study evaluated the safety and utility of TAS using a breast biopsy clip inserted into a metastatic lymph node and a point marker consisting of a short hook wire and nylon thread to remove the clipped lymph node.
Patients with breast cancer and clinically confirmed metastases to one-to-three axillary lymph nodes were included in this study. A breast biopsy clip was inserted into the metastatic lymph nodes before neoadjuvant chemotherapy. TAS was performed in patients with ycN0 disease after neoadjuvant chemotherapy. The lymph nodes containing the clips were removed using a point marker. The success criteria for TAS were the removal of the lymph node into which the clip was inserted using a point marker and the identification of the sentinel lymph node. The false-negative rate was calculated for cases in which TAS and axillary lymph node dissection were performed.
Thirty individuals from two institutions were enrolled between May 2021 and November 2022, of whom 20 underwent TAS. Ten patients had clinically positive axillary lymph nodes and underwent axillary lymph node dissection. No adverse events were observed in any patient using the clips or point markers. TAS was successful in 18 of the 20 patients (90%). Seven patients underwent TAS and axillary lymph node dissection with a false-negative rate of 0%.
The use of clips and point markers to perform TAS is clinically feasible.
定制腋窝手术(TAS)是一种选择性切除转移性淋巴结的新方法。本研究通过在转移性淋巴结中插入乳腺活检夹,并使用短钩丝和尼龙线组成的点标记物来移除夹闭的淋巴结,评估了 TAS 的安全性和实用性。
本研究纳入了经临床证实有 1 至 3 个腋窝淋巴结转移的乳腺癌患者。在新辅助化疗前,将乳腺活检夹插入转移性淋巴结。新辅助化疗后,对 ycN0 疾病患者进行 TAS。使用点标记物移除含有夹闭的淋巴结。TAS 的成功标准是使用点标记物移除插入夹闭的淋巴结,并识别前哨淋巴结。计算了在 TAS 和腋窝淋巴结清扫术均进行的情况下的假阴性率。
2021 年 5 月至 2022 年 11 月,来自两个机构的 30 名患者入组,其中 20 名患者接受了 TAS。10 名患者有临床阳性腋窝淋巴结,行腋窝淋巴结清扫术。在使用夹和点标记物的任何患者中均未观察到不良事件。20 名患者中有 18 名(90%)成功进行了 TAS。7 名患者同时进行了 TAS 和腋窝淋巴结清扫术,假阴性率为 0%。
使用夹和点标记物进行 TAS 在临床上是可行的。